Partial suppression of estradiol: a new strategy in endometriosis management?
Other
OA: closed
CC0
⤵ 27 in-corpus citations
AI-generated summary
This paper explores the potential of partially suppressing estradiol as a novel therapeutic strategy for managing endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (5)
- Elagolix, an oral gonadotropin-releasing hormone antagonist, for the management of endometriosis-associated pain: safety and efficacy results from two double-blind, randomized, placebo-controlled studies via openalex
- Estrogen-progestins and progestins for the management of endometriosis via openalex
- Hormone treatment of endometriosis: the estrogen threshold hypothesis via openalex
- Oxidative stress in the pelvic cavity and its role in the pathogenesis of endometriosis via openalex
- Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills via openalex
Cited by (29)
- Deep Infiltrating Endometriosis Influence of Endometriosis and progestin therapy on the course of COVID infection A prospective study at a university endometriosis center in Germany 2026
- Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review 2026
- Endometriosis and Endometriosis-Associated Tumors 2025
- How to Protect Fertility Potential in Endometriosis 2024
- Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3) 2024
- Horizons in Endometriosis: Proceedings of the Montreux Reproductive Summit, 14-15 July 2023 2024
- Oral GnRH Antagonists in Combination with Estradiol and Norethindrone Acetate for Pain Relief Associated with Endometriosis: A Review of Evidence of a Novel Class of Hormonal Agents 2024
- Endometriosis and Endometriosis-Associated Tumors 2024
- A Lifelong Impact on Endometriosis: Pathophysiology and Pharmacological Treatment 2023
- Cannabis and Endometriosis: The Roles of the Gut Microbiota and the Endocannabinoid System 2023
- A review of phase II and III drugs for the treatment and management of endometriosis 2023
- Evolution of uterine adenomyosis volume during and after GnRH antagonist (linzagolix) treatment: lessons for further clinical trials 2023
- Hormonal drugs for the treatment of endometriosis 2022
- Conservative surgical and drug therapies for adenomyosis Medicine 2022
- Novel pharmacological therapies for the treatment of endometriosis 2022
- Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review 2021
- Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New 'Hit Hard First and then Maintain' Regimen of Administration 2021
- Uterine Adenomyosis: From Disease Pathogenesis to a New Medical Approach Using GnRH Antagonists 2021
- Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial 2020
- Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis 2020
- EFFICIENCY OF MEDICATION THERAPY IN THE COMPLEX TREATMENT OF ENDOMETRIOSIS: RETROSPECTIVE ANALYSIS OF DATA 2019
- Endometriosis and Endometriosis-Associated Tumors 2019
- Medical treatment of endometriosis-related pain 2018
- Pathogenesis of endometriosis: Interaction between Endocrine and inflammatory pathways 2018
- Medical treatment in the management of deep endometriosis infiltrating the proximal rectum and sigmoid colon: a comprehensive literature review 2018
- Progesterone resistance in endometriosis: origins, consequences and interventions 2017
- Meta-Analysis of Chinese Traditional Medicine Bushen Huoxue Prescription for Endometriosis Treatment 2017
- Role of medical therapy in the management of deep rectovaginal endometriosis 2017
- Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109 2017
Source provenance
- europepmc
- last seen: 2026-10-10T06:11:15.153948+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:19:26.535059+00:00
- unpaywall
- last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0
· commercial use OK